PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic

Menopause

Coverage of menopause across PatientSpotlight - the developments worth watching, the access reality, and what the next twelve months may bring. 2 pieces on this topic across therapy areas, newest first within each collection.

← All topics

Signals

1
SignalApr 26, 2026FDA · industry-filing · peer-reviewed

Non-hormonal vasomotor symptom options are now in routine use

Fezolinetant uptake has been faster than analyst projections, and the field is now in the post-launch phase where prescribing patterns, payer coverage, and longer real-world safety data shape adoption.

TreatmentMenopauseRegulatorySafety

Explained

1
ExplainedApr 26, 2026FDA · peer-reviewed · industry-filing

Why 'women's health' is being rebuilt from a neglected indication frame to a commercial category

For most of the modern pharmaceutical era, 'women's health' meant contraception and hormone-replacement therapy. The conditions outside that frame - endometriosis, polycystic ovary syndrome, menopause symptoms, female-specific cardiovascular and metabolic conditions - were under-funded relative to disease burden. That is changing structurally, and the commercial implications are larger than any single therapy.

FrameworkCategoryEndometriosisMenopause